Successful treatment of orbital myositis with intravenous immunoglobulins

Shambal, S.; Lindner, Alfred; Zierz, Stephan

doi:10.1002/(sici)1097-4598(199810)21:10<1359::aid-mus26>3.3.co;2-s

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient was treated transiently with azathioprine because of gastric intolerance associated with 12 monthly doses of IVIG; a marked improvement in ocular signs was observed, but at 12 months deterioration was observed on magnetic resonance imaging (MRI); the patient was then treated by methotrexate and corticosteroids. Successful treatment of a case of orbital myositis has also been reported with IVIG 43 …”

Section: Efficacy Of Ivig In Interocular Inflammation: the Clinical Ementioning

confidence: 97%

Human Immunoglobulins in Intraocular Inflammation

Tellier

2007

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Chronic intraocular inflammation (IOI) is a heterogeneous group of rare diseases, which represents one of the leading causes of acquired and treatable blindness in adults. The main anatomical site of inflammation is the uveal tract, which is the vascular organ of the eye, but uveitis is now used to describe IOI more globally. In around 40% of the cases of uveitis an underlying systemic disease, often of autoimmune origin, can be identified. In autoimmune diseases with IOI, uveitis may be the first clinical manifestation and may represent the most severe sign. Studies in animal models, especially in experimental autoimmune uveitis (EAU), offer the opportunity to investigate the pathogenicity of these disorders. The conventional treatment of IOI includes corticosteroids and immunosuppressive agents, which are efficient in around one-half of the patients, but their effectiveness is also limited by their iatrogenicity. The effects of intravenous immunoglobulins (IVIGs) on ocular inflammation have been investigated in a wide spectrum of autoimmune/systemic diseases. Most of the publications are case series or open trials. They show favorable results in a subset of indications, including mainly ocular cicatricial pemphigoid (OCP), Vogt-Koyanagi-Harada (VKH) syndrome, or birdshot disease. Efficacy results are more debated in other conditions such as inflammatory demyelinating optic neuritis. In other diseases with IOI only case reports are available, suggesting that IVIGs may be of some interest. These observations support the need for controlled trials to demonstrate the efficacy of IVIGs and assess their potential steroid-sparing effect.

show abstract

Section: Efficacy Of Ivig In Interocular Inflammation: the Clinical Ementioning

confidence: 97%

Human Immunoglobulins in Intraocular Inflammation

Tellier

2007

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

Successful treatment of orbital myositis with intravenous immunoglobulins

Cited by 1 publication

References 0 publications

Human Immunoglobulins in Intraocular Inflammation

Human Immunoglobulins in Intraocular Inflammation

Contact Info

Product

Resources

About